Braftovi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Encorafenib

Indications/Uses

In combination w/ binimetinib for adult patients who have unresectable or metastatic melanoma w/ BRAF V600E or V600K mutation as detected by validated test. In combination w/ cetuximab for adult patients who have metastatic colorectal cancer w/ BRAF V600E mutation as detected by validated test & who have received prior systemic therapy.

Dosage/Direction for Use

Melanoma Recommended dose: 450 mg once daily in combination w/ binimetinib. Colorectal cancer Recommended dose: 300 mg once daily in combination w/ cetuximab.

Administration

May be taken with or without food: Swallow whole w/ water. Avoid grapefruit juice.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EC03 - encorafenib ; Belongs to the class of B-Raf serine-threonine kinase (BRAF) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Braftovi cap 50 mg

Packing/Price

1's

Form

Braftovi cap 75 mg

Packing/Price

1's

Braftovi

Manufacturer:

Pierre Fabre Medicament